IntegerBio is a biotechnology company developing a new class of host-directed immunomodulators designed to safely harness the therapeutic potential of the type I interferon (IFN) pathway across oncology and infectious disease. The company’s proprietary SYNFERON™ platform enables the engineering of biologics that cross-link the type I IFN receptors (IFNAR1 and IFNAR2) to deliver tunable, partial agonism of IFN signaling. This approach is intended to preserve the powerful antiviral and immune-activating biology of interferons while improving tolerability and safety, overcoming historical limitations of conventional IFN therapies driven by inflammatory cytokine induction and anti-proliferative toxicities.